Clinical Trial Update: Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial is examining ursodeoxycholic acid as a supplement to standard therapy to prevent recurrence of Clostridioides difficile infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• Ursodeoxycholic acid (ursodeoxycholic acid)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Clostridioides Difficile Infection | EARLY_Phase 1 | Status: NOT_YET_RECRUITING